Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

Summary

The purpose of the study is to investigate the drug octreotide acetate in a new intranasal formulation and compare it to the FDA-approved subcutaneous (SC) injection formulation. The two octreotide acetate formulations will be evaluated following separate administrations for safety and tolerability including any side effects, the speed at which the drug is absorbed and eliminated in the body, and the ability of the drug to lower the levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).

Timeline

Start

2017-01

Primary completion

2017-03

Completion

2017-03

Drugs

Indications

No indication recorded.